envafolimab + neoadjuvant chemotherapy

This combination therapy consists of envafolimab, a recombinant humanized single-domain PD-L1 antibody, administered in conjunction with standard neoadjuvant chemotherapy regimens, specifically the MAP (methotrexate, doxorubicin, and cisplatin) or DIA (doxorubicin, ifosfamide, and cisplatin) regimens. Envafolimab is unique as a PD-L1 inhibitor due to its subcutaneous administration and its structure as a single-domain antibody fused with a human IgG1 Fc fragment. It works by blocking the interaction between PD-L1 on tumor cells and PD-1 on T-cells, thereby reversing immune suppression and enhancing anti-tumor T-cell activity. The chemotherapy components provide direct cytotoxic effects: methotrexate inhibits dihydrofolate reductase to disrupt DNA synthesis; doxorubicin intercalates DNA and inhibits topoisomerase II; cisplatin forms DNA cross-links; and ifosfamide acts as an alkylating agent. This combined approach is being evaluated in Phase 2 clinical trials by Shanghai General Hospital to improve the rate of complete tumor resection and clinical outcomes in patients with resectable stage IIb osteosarcoma.

Other names

envafolimab + MAP regimenenvafolimab + DIA regimen